LCL161 is an IAP inhibitor that inhibits XIAP in HEK293 cells and cIAP1 in MDA-MB-231 cells with IC50s of 35 and 0.4 nM, respectively. LCL-161 is a small molecule second mitochondrial activator (SMAC) mimetic that both dissociates IAP from caspases and induces proteasomal degradation of cIAP-1 and -2, resulting in Alterations in signaling through the NFκB pathway enhance TNF production and apoptosis mediated by the extrinsic pathway.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
